Jeffrey M. Leiden - 01 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role: Executive Chairman, Director
Signature: /s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol: VRTX
Transactions as of: 01 Feb 2022
Net transactions value: -$1,529,753
Form type: 4
Filing time: 03 Feb 2022, 15:19:24 UTC
Next filing: 22 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRTX	Common Stock	Award	$0	+28,444	+57%	$0.000000	78,232	01 Feb 2022	Direct	F1
transaction	VRTX	Common Stock	Award	$0	+20,928	+27%	$0.000000	99,160	01 Feb 2022	Direct	F2
transaction	VRTX	Common Stock	Award	$0	+17,445	+18%	$0.000000	116,605	01 Feb 2022	Direct	F3
transaction	VRTX	Common Stock	Tax liability	$1,529,753	-6,279	-5.4%	$243.63	110,326	02 Feb 2022	Direct
holding	VRTX	Common Stock						440	01 Feb 2022	401(k)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2	Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/17/2022.
F3	Restricted stock unit award that fully vested upon grant.

Remarks:

Exhibit 24 - Power of Attorney